Loading stock…

GeneDx Holdings Corp. (WGS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

GeneDx Holdings Corp.

WGSMarket cap $2.13BPrice $71.5

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Sequences DNA and RNA to diagnose rare genetic diseases, turning years-long diagnostic odysseys into days. Its database of over 2 million tested patients makes pattern-matching rare mutations faster and more accurate than almost anyone else in the industry.

In Bastion Portfolios?

52W Return-41%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+22%9

Revenue Forecast

Rev CAGR (1y)+13%7

Rev CAGR (3y)+19%9

Rev CAGR (5y)+20%9

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+1148%10

EPS Growth Y+3+69%10

Quality

Margins

EBIT Margin-13%1

Net Income Margin-23%1

Free Cash Flow Margin-17%2

Debt

Net Debt/EBITDAna–

Efficiency

ROE-41%1

ROA-23%1

Earnings Stability22

GEAR+VERY WEAK13

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)1051

P/E Ratio (Forward 3y)311

P/BV8.72

EV Multiples

EV/EBITDA Fwd3551

EV/EBIT Fwd3881

Yield

Free Cash Flow Yield-3.6%2

Dividend Yieldna–

Momentum

Short term

1 month return-17%1

3 month return+9%8

YTD return-45%1

Mid term

Price vs 52wHigh42%1

1 year return-41%1

Long term

3 year return+2054%10

5 year return-72%1

Risk Shield

Price Risk

Beta1.04

Volatility97%1

Free Cash Flow

Free Cash Flow Margin-17%2

Free Cash Flow Yield-3.6%2

Quality

ROCE-15%1

Earnings Stability22

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

WGSGeneDx Holdings

Revenue FY25$428M

GROWTH RATING↗

VERY STRONG88 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+22%9

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+19%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+1148%10

EPS growth, FY28E+69%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 88% of companies worldwide.

Revenue grew 22%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 19%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

Revenue grew 22%/yr over the last 3 years; forecasts see it cooling to 19%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-17%1

3-month return+9%8

YTD return-45%1

MID & LONG-TERM▾SCORE

% of 52-week high42%1

1-year return-41%1

3-year return+2054%10

5-year return-72%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+9%).

WATCH

Average long-term results. Multi-year returns are middling (+2054% over three years and -72% over five), roughly average for the market.

WEAKNESSES

It's down 41% over the past year, now 58% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-17%) and so far this year (-45%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on GeneDx Holdings Corp.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

WGSGeneDx Holdings

Revenue FY25$428M

GROWTH RATING↗

VERY STRONG88 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+22%9

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+19%9

Revenue, next 5Y, CAGR+20%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+1148%10

EPS growth, FY28E+69%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 88% of companies worldwide.

Revenue grew 22%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 19%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 20%/yr over five years.9/10

WATCH

Revenue grew 22%/yr over the last 3 years; forecasts see it cooling to 19%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK21 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-17%1

3-month return+9%8

YTD return-45%1

MID & LONG-TERM▾SCORE

% of 52-week high42%1

1-year return-41%1

3-year return+2054%10

5-year return-72%1

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+9%).

WATCH

Average long-term results. Multi-year returns are middling (+2054% over three years and -72% over five), roughly average for the market.

WEAKNESSES

It's down 41% over the past year, now 58% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-17%) and so far this year (-45%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on GeneDx Holdings Corp.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community